Markets · 1 sources covering this

Palantir Is Stuck in Worst-of-Both-Worlds Bind With AI, Software

It’s been a sobering stretch for Palantir Technologies Inc. shareholders, who have watched their once high-flying positions lose more than 40% of their value since the stock hit a peak in November.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

1 L · 0 C · 0 R

How 1 sources are covering this

BloombergLean L·2h ago
Palantir Is Stuck in Worst-of-Both-Worlds Bind With AI, Software
It’s been a sobering stretch for Palantir Technologies Inc. shareholders, who have watched their once high-flying positions lose more than 40% of their value since the stock hit a peak in November.
Read at Bloomberg →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/240bb8fa4e17a156d317fa1a68bdcbf0b8c61945"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Palantir Is Stuck in Worst-of-Both-Worlds Bind With AI, Software"></iframe>

Palantir Is Stuck in Worst-of-Both-Worlds Bind With AI, Software

How 1 sources are covering this

Palantir Is Stuck in Worst-of-Both-Worlds Bind With AI, Software

More from Markets

Gold is still in its ‘explosive phase,’ says Deutsche Bank, as it sticks to year-end target

Chile Peso Bonds Face Pressure if Strait of Hormuz Stays Closed

Nigeria’s Top Bank Offers $1 Billion Shares Held by Bridge Firm

An AstraZeneca, Bristol Myers Squibb merger could create a cancer-drug giant, but analysts call it ‘odd’

Reader

Trust & legal

Across the network

How 1 sources are covering this

Palantir Is Stuck in Worst-of-Both-Worlds Bind With AI, Software

More from Markets

Gold is still in its &#x2018;explosive phase,&#x2019; says Deutsche Bank, as it sticks to year-end target

Chile Peso Bonds Face Pressure if Strait of Hormuz Stays Closed

Nigeria’s Top Bank Offers $1 Billion Shares Held by Bridge Firm

An AstraZeneca, Bristol Myers Squibb merger could create a cancer-drug giant, but analysts call it &#x2018;odd&#x2019;

Reader

Trust & legal

Across the network

Gold is still in its ‘explosive phase,’ says Deutsche Bank, as it sticks to year-end target

An AstraZeneca, Bristol Myers Squibb merger could create a cancer-drug giant, but analysts call it ‘odd’